High-throughput screening of pro-resolving compounds for spinal cord injury
This innovative research utilizes high-throughput screening (HTS) to identify compounds that resolve maladaptive inflammation in spinal cord injuries, promoting tissue repair and functional recovery. Leveraging advanced imaging and in vitro models, the project aims to discover pro-resolving drugs.
Overview
This research initiative focuses on identifying pro-resolving compounds that can address the maladaptive inflammatory response following spinal cord injury (SCI). The goal is to shift the injured environment from a chronic pro-inflammatory state to one that supports tissue protection, regeneration, and functional recovery. Utilizing high-throughput screening (HTS) assays, the project aims to discover novel drugs that promote wound healing and neuroprotection in SCI patients.
Technical specifications
The project leverages advanced high-throughput screening systems equipped with high-content imaging to evaluate a vast array of compounds. Key technical elements include:
- In vitro models: Utilizes the foamy macrophage model, which mimics SCI-associated chronic inflammation.
- High-content imaging: Quantifies lipid accumulation, macrophage morphology, and viability, alongside inflammatory and pro-resolving markers.
- Screening and Validation: Promising compounds are ranked based on efficacy and toxicity, followed by comprehensive in vitro validation involving wound-healing protocols and regenerative responses.
Technology readiness level
The project is currently at Technology Readiness Level 3, indicating that the technology is in the active research and development phase with experimental proof-of-concept achieved in the lab environment.
About University of Minho
The University of Minho is a comprehensive public research university spanning campuses in Braga and Guimarães, serving a large student community in one of Portugal’s most industrialized regions. Industry engagement is enabled by co‑located campus labs, proximity to the International Iberian Nanotechnology Laboratory in Braga, and a science and technology park in Guimarães that hosts startups and R&D units. Clinical translation is organized through an academic clinical center that links the university with the regional hospital network to support regulated trials and real‑world studies. Research is supported by competitive European and national funding, including the European Commission and Portugal’s Foundation for Science and Technology (FCT). TecMinho, the university’s technology transfer interface, provides IP management, licensing, and venture support for industry partners.
Inquire about this partnering listing
Industry applications
delivered to your inbox.